Found: 9
Select item for more details and to access through your institution.
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1285, doi. 10.1007/s40263-022-00965-7
- By:
- Publication type:
- Article
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1269, doi. 10.1007/s40263-022-00963-9
- By:
- Publication type:
- Article
Comment on: "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder".
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1331, doi. 10.1007/s40263-022-00966-6
- By:
- Publication type:
- Article
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson's Disease.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1249, doi. 10.1007/s40263-022-00973-7
- By:
- Publication type:
- Article
Acknowledgement to Referees.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1243, doi. 10.1007/s40263-022-00972-8
- Publication type:
- Article
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1313, doi. 10.1007/s40263-022-00971-9
- By:
- Publication type:
- Article
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1301, doi. 10.1007/s40263-022-00970-w
- By:
- Publication type:
- Article
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects.
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1325, doi. 10.1007/s40263-022-00969-3
- By:
- Publication type:
- Article
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".
- Published in:
- CNS Drugs, 2022, v. 36, n. 12, p. 1333, doi. 10.1007/s40263-022-00967-5
- By:
- Publication type:
- Article